Satoru Kuriyama

TL;DR: The present study suggests that anemia, per se, is a factor in the progression of end-stage renal failure and that reversal of anemia by EPO can retard the progress of renal failure, especially in nondiabetic patients, provided that blood pressure control, rate of increase in Ht, and dietary protein restriction are appropriate.

TL;DR: The Japanese Society for Dialysis Therapy guideline committee, chaired by Dr Y. Tsubakihara, presents the Japanese guidelines, which replace the “2004 JSDT Guidelines for Renal Anemia in Chronic Hemodialysis Patients,” and contain new, additional guidelines for peritoneal dialysis, non‐dialysis (ND), and pediatric chronic kidney disease (CKD) patients.

TL;DR: Analysis of the clinical course of the three ACE genotypes revealed that the majority (95%) of patients with the DD genotype who had albuminuria progressed to end-stage renal disease within 10 years of diagnosis of diabetes.

TL;DR: In the current study, switching from glucose-containing dialysis solution to icodextrin resulted in improved lipid profiles and possibly a favorable metabolic profile, particularly in patients with poor glycemic control.

TL;DR: The clinical outcome of EPS in all patients who developed EPS between the period before and after the year of 1997 is summarized, and corticosteroid was given orally to the patients with EPS in addition to the conventional treatment.